Abstract Biologics targeting multiple pathways and/or cell types simultaneously have the potential to restore normal immune homeostasis. Inhibitory checkpoint receptor agonism by antibodies benefits from higher order clustering for strong activation, which can be achieved antibody Fc binding gamma receptors (FcγRs). However, many of current agonist non discriminately bind activating FcγRs. This...